ANURAS · Concall Summary
ANUPAM RASAYAN INDIA LTD
Anupam Rasayan India Limited reported a strong start to FY27, with consolidated total income growing by 36% year-on-year, reaching INR 668 crores. Management highlighted the successful commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry, marking a significant milestone as the first global company to do so. The company also signed a Letter of Intent with BASQUEVOLT for a potential long-term supply agreement valued at approximately USD 300 million. The acquisition of Jayhawk Fine Chemicals is enhancing Anupam's global platform, providing a strategic manufacturing base in the U.S. and expanding capabilities in high-value markets. Management noted that the proposed acquisition of Bliss GVS Pharma is progressing as planned, aiming to create a more integrated pharmaceutical platform. The earnings call emphasized the importance of these strategic initiatives in driving future growth and value creation.
Management emphasized strong growth and strategic advancements during the earnings call.
View source filing →Earlier concalls
- 2026-08-14 — Anupam Rasayan India Limited's investor presentation for Q1 FY27 reported a consolidated total revenue of ₹6,675 million…
- 2026-05-30 — Anupam Rasayan India Limited reported a landmark year in FY '26, achieving its highest ever revenue, driven by strong ex…
- 2026-05-23 — Anupam Rasayan India Limited submitted an investor presentation regarding its acquisition of Bliss GVS Pharma Limited. T…
See ANURAS's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free